MHealth to Improve Measles Immunization in Guinea-Bissau: Study Protocol for a Randomized Controlled Trial.

Tuesday, 2nd of August 2016

JMIR Res Protoc. 2016 Jul 27;5(3):e158. doi: 10.2196/resprot.5968.

MHealth to Improve Measles Immunization in Guinea-Bissau: Study Protocol for a Randomized Controlled Trial.

Rossing E¹ Ravn H Batista CS Rodrigues A.

Author information

Abstract

BACKGROUND:

Recent studies have revealed a low measles vaccination (MV) rate in the Republic of Guinea-Bissau (West Africa) that has not increased in accordance with the increasing coverage of other vaccinations. Measles is the deadliest of all childhood rash/fever illnesses and spreads easily implying that if the vaccination coverage is declining there is a significant risk of new measles outbreaks [27]. Meanwhile mobile health (mHealth; the use of mobile phones for health interventions) has generated much enthusiasm and shown potential in improving health service delivery in other contexts.

OBJECTIVE:

The aim of this study is to evaluate the efficiency of mHealth as a tool for improving MV coverage while contributing to the mHealth evidence base.

METHODS:

This study will take place at three health centers in different regions of Guinea-Bissau. Participants defined as mothers of the children receiving the MV will be enrolled when they arrive with their children at the health center to receive the Bacillus Calmette-Guérin vaccination usually within one month of the childs birth. Enrolment will continue until a study population of 990 children has been reached. The participants will be randomly assigned to a control arm or one of two intervention arms. Each of the three groups will have 330 participants distributed equally between health centers. Participants in the first intervention arm will receive a scheduled short message service (SMS) text message reminding them of the MV. Participants in the second intervention arm will receive a voice call in addition to the SMS message while the control arm will receive no interventions. The MV is scheduled to be administered at 9 months of age. Although the vaccine would still be effective after 12 months local policy in Guinea-Bissau prevents children aged >12 months from receiving the vaccination and thus the study will follow-up with participants after the children reach 12 months of age. Children who have not yet received the MV will be offered vaccination by the project group.

RESULTS:

The study will analyze the efficiency of the intervention by determining its overall effect on MV coverage and timeliness when children reach 12 months of age. The main analysis will be stratified by intervention group health center level of education ethnic group and role of the person receiving the text messages (eg mother father other family member). Secondary outcomes include the average number of health center visits (with intention to obtain the MV) required before successful administration.

CONCLUSIONS:

Despite the rapid proliferation of mHealth projects only a small number have been evaluated in terms of direct links to health outcomes. This gap in knowledge requires solid evidence on which policy-makers can base decisions. This study aims to produce significant knowledge about mHealth implementation within a Sub-Saharan context while creating data-supported evidence.

TRIAL REGISTRATION:

Clinicaltrials.gov: NCT02662595; https://clinicaltrials.gov/ct2/show/NCT02662595 (Archived by WebCite at http://www.webcitation.org/6jH8YiSjY).